Inhaled nitric oxide in ARDS
Section snippets
ENDOGENOUS NITRIC OXIDE
The critical role of an intact and functional endothelium in modulating vascular tone was realized more than 20 years ago. In 1980, Furgott and Zawadzki 29 reported that acetylcholine-induced vasodilation of arterial vascular smooth muscle required an endothelial-derived relaxing factor (EDRF) that was released by the endothelial cells and diffused into adjacent smooth muscle cells where it activated soluble guanylate cyclase and increased intracellular cGMP levels. In 1987, two groups of
INHALED NITRIC OXIDE
Nitrogen oxides are naturally occurring gases in the environment, although under normal conditions their concentrations are extremely small. Nitric oxides are produced when nitrogen and oxygen are combined with heat. Nitric oxide and nitrogen dioxide (NO2) are found in polluted air, decaying organic material and cigarette smoke.66 The Occupational Safety and Health Administration (OSHA) has set a tolera ble exposure limit for nitric oxides of 25 ppm for up to 8 hours per day.
When inhaled, NO
EFFECTS OF INHALED NITRIC OXIDE ON PULMONARY VASCULAR TONE
Numerous studies have demonstrated that endogenous NO is important in modulating pulmonary vascular tone in healthy people15, 85 and that impaired synthesis of endogenous NO may be involved in the pathophysiology of primary and secondary pulmonary arterial hypertension.35 Inhibition of endogenous NO synthesis has been shown to augment acute hypoxic pulmonary vasoconstriction and the pulmonary vasoconstrictor effects of many agents such as endothelin-1, angiotensin II, and thromboxane.2, 3 In
EFFECT OF INHALED NITRIC OXIDE ON GAS EXCHANGE
Although the initial rationale for the use of iNO in lung disease was to improve pulmonary hemodynamics, the most striking effect of this therapy may be its ability to improve oxygenation markedly. This effect is in contrast to other pulmonary vasodilators that usually worsen gas exchange by indiscriminately decreasing pulmonary vascular tone in the poorly ventilated lung. Because it is a gas, iNO is delivered only to ventilated areas of the lung and preferentially to areas of the lung that are
EFFECT OF INHALED NITRIC OXIDE ON PULMONARY CAPILLARY PERMEABILITY AND INFLAMMATION
Inhaled NO can affect pulmonary vascular permeability through several mechanisms. First, by decreasing pulmonary venous tone, iNO may reduce hydrostatic forces in pulmonary capillaries.9, 14 Second, iNO may reduce pulmonary vascular permeability directly by inhibiting oxidant injury.21, 38, 75 Inhaled NO can act as a free radical scavenger and attenuate oxidative damage to pulmonary vascular endothelium. Finally, there is evidence that iNO can inhibit inflammatory responses in the lung. In one
NONRANDOMIZED CONTROLLED STUDIES OF INHALED NITRIC OXIDE IN ACUTE RESPIRATORY DISTRESS SYNDROME
Numerous trials of iNO in ARDS have been reported since the initial study by Rossaint and co-workers80 in 1993. Almost all these studies were single-cohort studies in which patients served as their own controls. These studies had several objectives: (1) to determine if iNO has beneficial effects on cardiopulmonary hemodynamics and gas exchange; (2) to demonstrate that iNO can be administered without ad verse effects to patients or staff; and (3) to determine the optimal dose of iNO. In earlier
RANDOMIZED, CONTROLLED TRIALS OF INHALED NITRIC OXIDE IN ACUTE RESPIRATORY DISTRESS SYNDROME
The results of nonrandomized trials strongly suggested that iNO produced significant improvements in PAP and oxygenation in most patients with ARDS. Furthermore, the studies suggested that the acute beneficial effects of iNO could be sustained during long-term treatment. These findings quickly raised hopes that the use of iNO in ARDS would improve outcome. The first three randomized, controlled trials of iNO in ARDS were published in 1998. Two of the reports were small studies from single
FAILURE OF INHALED NITRIC OXIDE TO IMPROVE OUTCOME IN ACUTE RESPIRATORY DISTRESS SYNDROME
It is unclear why randomized, controlled trials have failed to show that iNO improves outcome in ARDS. Previous studies have shown that most patients with ARDS do not die of hypoxic respiratory failure.62 Why then should a therapy that improves oxygenation affect mortality in ARDS? Previous studies have suggested that pulmonary arterial hy pertension contributes to mortality in ARDS.94 Reducing pulmonary arterial pressure with iNO was one reason to hope that survival in ARDS could be improved.
IMPROVING RESPONSE TO INHALED NITRIC OXIDE
Although most patients with acute lung injury will have some improvement in gas exchange, the degree of response is variable and may not be meaningful in a substantial number of patients. Many studies have attempted to identify clinical features that could help predict re sponse to iNO. A favorable response to iNO has been correlated with baseline pulmonary vascular tone,12, 78, 93 the degree of alveolar recruitment,76, 78 a high degree of initial venous admixture,81 increased cardiac output,8
COMBINATION THERAPIES WITH INHALED NITRIC OXIDE
Because of the unique mechanism by which it works, iNO may enhance the ability of other forms of ventilatory support to improve oxygenation. A number of studies have examined the effect of combining iNO and prone positioning in adult patients with ARDS.16, 34, 57, 72, 79 In most studies57, 72, 79 more patients responded to prone positioning than to iNO, and the improvement in oxygenation was slightly better with prone positioning than with iNO. The number of patients in each study was small,
THE FUTURE OF INHALED NITRIC OXIDE IN ADULT PATIENTS WITH ACUTE LUNG INJURY
Despite the lack of proven benefit in clinical outcomes, many investigators continue to evaluate iNO for short-term symptomatic treatment of hypoxemic respiratory failure and pulmonary vasoconstriction in adult patients. Randomized clinical studies of patients with carefully defined disease states characterized by severe pulmonary hypertension or hypoxemia still are needed to identify patients who may benefit from iNO. The combination of iNO with other agents that increase pulmonary vascular
References (96)
- et al.
NO in the lung
Respir Physiol
(1995) - et al.
Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease
Lancet
(1996) - et al.
Effect of different doses of inhaled nitric oxide on pulmonary capillary pressure and on longitudinal distribution of pulmonary vascular resistance in ARDS
Br J Anaesth
(1998) - et al.
Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans
J Am Coll Cardiol
(1996) - et al.
Oxidation of bound dioxygen in hemoproteins
J Inorg Biochem
(1981) - et al.
Nitric oxide improves hypoxaemia following reperfusion oedema after pulmonary thromboendarterectomy
Br J Anaesth
(1995) Nitric oxide in adult lung disease
Chest
(1999)- et al.
Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease
J Thorac Cardiovasc Surg
(1998) - et al.
Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn
J Pediatr
(1997) - et al.
Effectiveness of nitric oxide inhalation in septic ARDS
Chest
(1996)
Inhaled nitric oxide therapy
Mayo Clin Proc
Life-threatening status asthmaticus treated with inhaled nitric oxide
J Pediatr
Nitric oxide usage after posttraumatic pneumonectomy
Ann Thorac Surg
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation
Biochem Biophys Res Commun
Almitrine effect on nitric oxide inhalation in adult respiratory distress syndrome
Lancet
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
Lancet
Efficacy of inhaled nitric oxide in patients with severe ARDS
Chest
Inhalation of nitric oxide as a life-saving therapy in a patient after pulmonary embolectomy
Br J Anaesth
The combination of partial liquid ventilation and inhaled nitric oxide in the severe oleic acid lung injury model
Chest
ABO blood group and inhaled nitric oxide in acute respiratory distress syndrome
Lancet
Inhaled nitric oxide in acute respiratory failure in adults
Br J Anaesth
Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension
American Review of Respiratory Disease
Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia
J Clin Invest
The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide
Intensive Care Med
Large increase in cardiac output in a patient with ARDS and acute right heart failure during inhalation of nitric oxide
Acta Anaesthesiol Scand
Effect of inhaled nitric oxide on venous admixture depends on cardiac output in patients with acute lung injury and acute respiratory distress syndrome
Acta Anaesthesiol Scand
Inhaled nitric oxide reduces pulmonary transvascular albumin flux in patients with acute lung injury
Anesthesiology
Inhaled nitric oxide lowers pulmonary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury
Acta Anaesthesiol Scand
Response to inhaled nitric oxide in patients with acute right heart syndrome
Am J Respir Crit Care Med
Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome
Anesthesiology
Sildenafil can increase the response to inhaled nitric oxide
Anesthesiology
Inhaled nitric oxide reduces lung fluid filtration after endotoxin in awake sheep
Am J Respir Crit Care Med
Hemodynamic and gas exchange response to inhaled nitric oxide and prone positioning in acute respiratory distress syndrome patients
Crit Care Med
Nitric oxide and high frequency jet ventilation in a patient with bilateral bronchopleural fistulae and ARDS
Can J Anaesth
Inhaled nitric oxide in patients with pulmonary embolism
Intensive Care Med
Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis
Am J Respir Crit Care Med
Nitric oxide improves transpulmonary vascular mechanics but does not change intrinsic right ventricular contractility in an acute respiratory distress syndrome model with permissive hypercapnia
Crit Care Med
Inhaled nitric oxide pretreatment but not posttreatment attenuates ischemia-reperfusion-induced pulmonary microvascular leak
Anesthesiology
Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation
Am J Respir Crit Care Med
Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial
Crit Care Med
Effect of inhaled nitric oxide in combination with almitrine on ventilation-perfusion distributions in experimental lung injury
Intensive Care Med
Effect of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome
Am J Respir Crit Care Med
Inhaled nitric oxide
Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation
Anesthesiology
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
Nature
The biology of nitrogen oxides in the airways
Am J Respir Crit Care Med
Long-term inhalations with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome
Intensive Care Med
Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome
Eur J Clin Invest
Cited by (23)
Adjuncts to ventilatory support Part 1: Nitric oxide, surfactants, prostacyclin, steroids, sedation, and neuromuscular blockade
2013, Current Problems in SurgeryCitation Excerpt :The application of inhaledNO (iNO) is a therapeutic option to selectively influence pulmonary blood flow to improve arterial oxygenation and to decrease pulmonary artery pressure without relevant systemic side effects. Although randomized controlled trials demonstrate no survival benefit in patient populations covering the entire severity range of ALI, iNO represents a feasible rescue treatment for ARDS patients with severe refractory hypoxemia.11,12 iNO is provided via a system (Ikaria, Clinton, NJ) that delivers the desired concentration of the agent, in parts per million (PPM), into the humidifier in the inspiratory limb of the ventilator.
Inhaled Nitric Oxide and Inhaled Prostacyclin in Acute Respiratory Distress Syndrome: What is the Evidence?
2011, Critical Care ClinicsCitation Excerpt :In contrast, a study ALI patients with MPAP less than 30 mm Hg treated with iNO showed minimal decrease in MPAP.22 It was hypothesized that patients with greater degree of pulmonary hypertension in the presence of ARDS were more likely to respond to iNO.23 Even among patients with severe pulmonary hypertension, however, response to iNO was not uniform.
The Role of Mechanical Ventilation in Acute Brain Injury
2008, Neurologic ClinicsCitation Excerpt :These data contrasted with another study of ARDS patients who had TBI or intracerebral hemorrhage, in which prone positioning had no effect on ICP or CPP but significantly ameliorated oxygenation and respiratory system compliance [98]. Inhaled nitric oxide induces selective vasodilation in ventilated lung units, thereby decreasing ventilation-perfusion mismatch, improving oxygenation, and attenuating pulmonary hypertension [99]. A meta-analysis of randomized trials concluded that inhaled nitric oxide given to patients who have ALI/ARDS improves oxygenation but is not associated with any survival advantage and may even cause harm [100].
Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: Basic mechanisms to potential therapies
2004, Annals of Thoracic SurgeryCitation Excerpt :In the phase II trial by Dellinger and associates [86] examining the use of inhaled NO in ARDS, dose concentrations ranged from 1.25 to 80 ppm, and the authors reported no adverse effects except for increased methemoglobin concentration in the groups receiving 40 and 80 ppm. Despite this initial enthusiasm, recent studies question whether inhaled NO improves overall mortality in ARDS [86–88]. A limiting factor in the widespread use of inhaled NO is the potential toxicity of the substance, especially in high concentrations.
Critical role of nitric oxide in impeding COVID-19 transmission and prevention: a promising possibility
2022, Environmental Science and Pollution Research